vs
Arbutus Biopharma Corp（ABUS）与ASP Isotopes Inc.（ASPI）财务数据对比。点击上方公司名可切换其他公司
ASP Isotopes Inc.的季度营收约是Arbutus Biopharma Corp的1.6倍（$16.7M vs $10.7M），ASP Isotopes Inc.同比增速更快（1295.7% vs 522.2%）
Arbutus生物制药是一家公开上市的加拿大生物制药企业，专长于脂质体药物递送与RNA干扰技术，目前主要开展针对乙型肝炎感染的治疗药物研发工作，在抗病毒新药研发领域拥有深厚的技术积累。
ASP Isotopes Inc.是一家特种材料企业，专注于高纯度定制同位素的研发与生产，产品广泛应用于核医学、靶向抗癌治疗、清洁能源及工业研究等领域，客户覆盖北美、欧洲及亚太地区。
ABUS vs ASPI — 直观对比
营收规模更大
ASPI
是对方的1.6倍
$10.7M
营收增速更快
ASPI
高出773.5%
522.2%
损益表 — Q2 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $10.7M | $16.7M |
| 净利润 | $2.5M | — |
| 毛利率 | — | 12.5% |
| 营业利润率 | 13.9% | — |
| 净利率 | 23.5% | — |
| 营收同比 | 522.2% | 1295.7% |
| 净利润同比 | 112.7% | -586.8% |
| 每股收益（稀释后） | $0.01 | — |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ABUSASPI
| Q4 25 | — | $16.7M | ||
| Q3 25 | — | $4.9M | ||
| Q2 25 | $10.7M | — | ||
| Q4 23 | $2.1M | — | ||
| Q3 23 | $4.7M | — | ||
| Q2 23 | $4.7M | — | ||
| Q1 23 | $6.7M | — | ||
| Q4 22 | $6.2M | — |
净利润ABUSASPI
| Q4 25 | — | — | ||
| Q3 25 | — | $-12.9M | ||
| Q2 25 | $2.5M | — | ||
| Q4 23 | — | — | ||
| Q3 23 | $-20.1M | — | ||
| Q2 23 | $-17.1M | — | ||
| Q1 23 | $-16.3M | — | ||
| Q4 22 | $-21.9M | — |
毛利率ABUSASPI
| Q4 25 | — | 12.5% | ||
| Q3 25 | — | 8.7% | ||
| Q2 25 | — | — | ||
| Q4 23 | — | — | ||
| Q3 23 | — | — | ||
| Q2 23 | — | — | ||
| Q1 23 | — | — | ||
| Q4 22 | — | — |
营业利润率ABUSASPI
| Q4 25 | — | — | ||
| Q3 25 | — | -306.1% | ||
| Q2 25 | 13.9% | — | ||
| Q4 23 | -967.2% | — | ||
| Q3 23 | -462.8% | — | ||
| Q2 23 | -395.3% | — | ||
| Q1 23 | -260.4% | — | ||
| Q4 22 | -361.3% | — |
净利率ABUSASPI
| Q4 25 | — | — | ||
| Q3 25 | — | -263.7% | ||
| Q2 25 | 23.5% | — | ||
| Q4 23 | — | — | ||
| Q3 23 | -431.6% | — | ||
| Q2 23 | -367.5% | — | ||
| Q1 23 | -244.3% | — | ||
| Q4 22 | -351.2% | — |
每股收益（稀释后）ABUSASPI
| Q4 25 | — | — | ||
| Q3 25 | — | $-0.15 | ||
| Q2 25 | $0.01 | — | ||
| Q4 23 | $-0.12 | — | ||
| Q3 23 | $-0.12 | — | ||
| Q2 23 | $-0.10 | — | ||
| Q1 23 | $-0.10 | — | ||
| Q4 22 | $-0.13 | — |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $37.4M | $333.3M |
| 总债务越低越好 | $0 | $14.4M |
| 股东权益账面价值 | $83.0M | $204.2M |
| 总资产 | $103.3M | $498.0M |
| 负债/权益比越低杠杆越低 | 0.00× | 0.07× |
8季度趋势，按日历期对齐
现金及短期投资ABUSASPI
| Q4 25 | — | $333.3M | ||
| Q3 25 | — | $113.9M | ||
| Q2 25 | $37.4M | — | ||
| Q4 23 | $126.0M | — | ||
| Q3 23 | $17.5M | — | ||
| Q2 23 | $27.2M | — | ||
| Q1 23 | $40.6M | — | ||
| Q4 22 | $146.9M | — |
总债务ABUSASPI
| Q4 25 | — | $14.4M | ||
| Q3 25 | — | $13.9M | ||
| Q2 25 | $0 | — | ||
| Q4 23 | $0 | — | ||
| Q3 23 | $0 | — | ||
| Q2 23 | $0 | — | ||
| Q1 23 | $0 | — | ||
| Q4 22 | $0 | — |
股东权益ABUSASPI
| Q4 25 | — | $204.2M | ||
| Q3 25 | — | $74.1M | ||
| Q2 25 | $83.0M | — | ||
| Q4 23 | $106.0M | — | ||
| Q3 23 | $119.3M | — | ||
| Q2 23 | $134.7M | — | ||
| Q1 23 | $143.9M | — | ||
| Q4 22 | $136.9M | — |
总资产ABUSASPI
| Q4 25 | — | $498.0M | ||
| Q3 25 | — | $225.9M | ||
| Q2 25 | $103.3M | — | ||
| Q4 23 | $144.4M | — | ||
| Q3 23 | $158.6M | — | ||
| Q2 23 | $176.8M | — | ||
| Q1 23 | $191.2M | — | ||
| Q4 22 | $195.4M | — |
负债/权益比ABUSASPI
| Q4 25 | — | 0.07× | ||
| Q3 25 | — | 0.19× | ||
| Q2 25 | 0.00× | — | ||
| Q4 23 | 0.00× | — | ||
| Q3 23 | 0.00× | — | ||
| Q2 23 | 0.00× | — | ||
| Q1 23 | 0.00× | — | ||
| Q4 22 | 0.00× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-15.7M | $-37.8M |
| 自由现金流经营现金流 - 资本支出 | — | $-47.4M |
| 自由现金流率自由现金流/营收 | — | -284.7% |
| 资本支出强度资本支出/营收 | 0.0% | 57.9% |
| 现金转化率经营现金流/净利润 | -6.24× | — |
| 过去12个月自由现金流最近4个季度 | — | — |
8季度趋势，按日历期对齐
经营现金流ABUSASPI
| Q4 25 | — | $-37.8M | ||
| Q3 25 | — | $-8.9M | ||
| Q2 25 | $-15.7M | — | ||
| Q4 23 | $-17.3M | — | ||
| Q3 23 | $-21.8M | — | ||
| Q2 23 | $-19.6M | — | ||
| Q1 23 | $-27.3M | — | ||
| Q4 22 | $-17.0M | — |
自由现金流ABUSASPI
| Q4 25 | — | $-47.4M | ||
| Q3 25 | — | $-12.0M | ||
| Q2 25 | — | — | ||
| Q4 23 | — | — | ||
| Q3 23 | $-21.8M | — | ||
| Q2 23 | $-20.4M | — | ||
| Q1 23 | $-27.4M | — | ||
| Q4 22 | $-17.1M | — |
自由现金流率ABUSASPI
| Q4 25 | — | -284.7% | ||
| Q3 25 | — | -245.5% | ||
| Q2 25 | — | — | ||
| Q4 23 | — | — | ||
| Q3 23 | -468.4% | — | ||
| Q2 23 | -439.0% | — | ||
| Q1 23 | -410.0% | — | ||
| Q4 22 | -274.2% | — |
资本支出强度ABUSASPI
| Q4 25 | — | 57.9% | ||
| Q3 25 | — | 64.4% | ||
| Q2 25 | 0.0% | — | ||
| Q4 23 | 0.0% | — | ||
| Q3 23 | 0.7% | — | ||
| Q2 23 | 18.5% | — | ||
| Q1 23 | 1.7% | — | ||
| Q4 22 | 2.1% | — |
现金转化率ABUSASPI
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | -6.24× | — | ||
| Q4 23 | — | — | ||
| Q3 23 | — | — | ||
| Q2 23 | — | — | ||
| Q1 23 | — | — | ||
| Q4 22 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
